Shares of Compugen Ltd. (NASDAQ:CGEN) were up 3.9% during trading on Wednesday . The stock traded as high as $6.69 and last traded at $6.67, with a volume of 63,362 shares. The stock had previously closed at $6.42.

Several analysts recently commented on CGEN shares. FBR & Co reaffirmed a “buy” rating on shares of Compugen in a report on Thursday, May 12th. Zacks Investment Research downgraded shares of Compugen from a “hold” rating to a “sell” rating in a report on Tuesday, July 12th. One research analyst has rated the stock with a sell rating and six have given a buy rating to the stock. The stock currently has an average rating of “Buy” and an average target price of $10.79.

The stock’s market capitalization is $337.17 million. The company’s 50-day moving average is $6.64 and its 200 day moving average is $6.03.

Compugen Ltd. (Compugen) is a therapeutic discovery company. The Company focuses on the discovery and development of monoclonal antibodies (mAbs) and therapeutic proteins in the fields of oncology and immunology. Its pipeline program consists of drug targets and therapeutic product candidates at various stages ranging from target validation to pre-clinical studies in the fields of oncology and immunology, with a primary focus on immuno-oncology.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.